Peptides Before and After Results and How to Weigh the Evidence

Peptides before and after posts are among the most shared claims in the field, and the pictures carry very different weight depending on the molecule. For approved peptide drugs, the before and after is a measured number from a large trial with a placebo group. For unapproved ones it is usually a photo with no control. This case sets the two kinds of evidence side by side and offers a way to weigh any claim. It names no vendors, prices, doses or sources for buying unapproved products.

What a Fair Before and After Needs

A before and after picture is a story of change, but change has many causes. Skin changes with season, light and sleep. Injuries heal on their own, and many people join a study or start a product when symptoms are at their worst, so a later improvement can be partly a return to average. A fair comparison needs a control group, the same measurement before and after, outcomes chosen in advance, blinded assessors and a report on every participant, including those who dropped out. Without those, an image can be real and still prove nothing about the product. A trial turns the picture into a number that someone else can check.

The control group matters more than most readers expect, because the placebo group also has a before and after. In the semaglutide STEP 1 trial, people given placebo plus lifestyle support lost about 2.4 percent of body weight over 68 weeks, and in the tirzepatide SURMOUNT 1 trial the placebo group lost about 3.1 percent over 72 weeks. Those drugs still beat placebo by a wide margin, but a photo of one person, with no comparison, cannot show how much of a change came from the drug. The same problem applies to any peptides before and after post: the missing group is the missing evidence.

Approved Peptide Drugs and Trial Measured Results

Approved peptide drugs show what good before and after evidence looks like. In STEP 1, 1,961 adults with obesity or overweight and no diabetes received once weekly semaglutide or placebo for 68 weeks, and mean body weight fell 14.9 percent against 2.4 percent, with nausea and diarrhea the common side effects. In SURMOUNT 1, 2,539 adults received tirzepatide at three dose levels or placebo for 72 weeks, and the mean loss ranged from 15.0 to 20.9 percent by dose, against 3.1 percent. Both trials were randomised and double blind, and both report confidence intervals, discontinuation rates and adverse events, which a photo never does.

Tesamorelin is a smaller and older example. In a 2007 trial of 412 people with HIV and excess abdominal fat, daily tesamorelin for 26 weeks cut visceral fat measured by CT by 15.2 percent while placebo increased it by 5.0 percent. Its label limits the use to excess abdominal fat in adults with HIV related lipodystrophy and says it is not for weight loss, because it is weight neutral. That limit is part of the evidence. A before and after chart for a drug should state what was measured, in whom, and over how long, and approved drugs also carry labels that say what they do not do.

Unapproved Peptides and the Photo Problem

Unapproved peptides usually come with photos instead of trials. For GHK Cu, topical studies exist but are mostly small, often run on facial creams and often funded by the cosmetic industry, according to reviews and a 2026 news report, and no published human study shows injected GHK Cu to be safe or effective. For BPC 157, a 2025 systematic review found one retrospective human report, in which 7 of 12 people reported relief after injections for knee pain, among 36 studies that were otherwise preclinical. That report is a lead, not a controlled trial. A photo, a testimonial or a sentence like it worked for me belongs below those records and not beside them.

Photos also fail for practical reasons. Lighting, angle, make up, filters, hydration, weight changes, other treatments and time of day all alter an image, and a poster chooses which pair to show. Nobody counts the people who saw no change or who stopped. At the July 2026 FDA advisory meeting a speaker said staff could not identify a single human clinical study of TB 500, yet pictures attached to that name circulate widely. The practical rule is that peptides before and after pictures for unapproved products are an invitation to ask for a trial, not a result, and the absence of a trial is the finding.

A Scorecard for Any Before and After Claim

A simple scorecard helps. Ask what the control was, how the outcome was measured and by whom, how many people started and how many finished, and whether the study was registered before it began. Ask also whether the product in the picture is the same as the product tested, since a vial sold online can differ from the material in a paper. For approved drugs, the label answers many of these questions. For unapproved peptides, most answers are missing, and a missing answer should lower the rating and not be filled in by hope. The table ranks common evidence types from strongest to weakest.

Applying the scorecard to the claim that photos show peptide results gives a split verdict. For approved peptide drugs the measured trial results are strong, and the claim holds only through those numbers. For unapproved peptides the photos stand alone, and they rate weak, with evidence strength 2 of 5 for the claim as a whole. Treat before and after peptides posts as prompts for questions and not proof. Ask a clinician about approved options, and follow registered trials if you want to keep an eye on an unapproved peptide. Registered trials list their outcomes in advance, which is the one feature a photo can never offer, and that makes them the better place to watch for real news.

Conclusion

Peptides before and after results can be trusted in proportion to the design behind them. Approved drugs such as semaglutide, tirzepatide and tesamorelin have trial numbers, control groups and labels. Unapproved peptides mostly have photos, small studies or animal work. Use the scorecard, ask for the control group, and keep health decisions with a clinician who can name an approved option.